Dendrite Announces First Quarter Earnings Conference Call

    Business Editors

    BEDMINSTER, N.J.--(BUSINESS WIRE)--April 21, 2005--Dendrite International, Inc. (NASDAQ: DRTE) today announced that it would release its first quarter earnings after the close of the market Thursday, April 28, 2005. A press release will be issued at 4 p.m. EST on that date, followed by a conference call at 5 p.m.
    Investors may call (800) 230-1093 (United States) or (612) 332-0634 (international) to access the conference call. In addition to the call, a link to a live simulcast will be available at www.dendrite.com in the Investors' Highlights section.
    For a replay of the conference call, investors may call (800) 475-6701 (United States) or (320) 365-3844 (international); access code is 780049.

    About Dendrite

    Founded in 1986, Dendrite International (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

    Note: Dendrite is a registered trademark of Dendrite International, Inc. The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. All "outlook" information constitutes forward-looking statements. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; dependence on major customers; economic pressures and legislative and regulatory impact on our customers; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; our ability to attract and retain key personnel; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; results from strategic relationships; risks associated with events that may affect the world economy, including terrorism, military action in the Middle East or threat of other hostilities in the Middle East, Asia and other geographical regions; catastrophic events which could negatively affect our information technology infrastructure; difficulties disposing of certain of our facilities; and unexpected changes in accounting regulations, standards or interpretations. Other important factors that should be considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.

--30--KK/ny*

CONTACT: Dendrite Investor Relations: Christine Croft, 908-443-4265 christine.croft@dendrite.com

KEYWORD: NEW JERSEY INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL EARNINGS CONFERENCE CALLS SOURCE: Dendrite International, Inc.

Copyright Business Wire 2005